-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$138.57-30.69% Downside
Prometheus Biosciences, Inc. Frequently Asked Questions
-
What analysts cover Prometheus Biosciences, Inc.?
Prometheus Biosciences, Inc. has been rated by research analysts at Stifel Nicolaus, Goldman Sachs, Oppenheimer, RBC Capital, BTIG, Credit Suisse in the past 90 days.